Clinical trials: FLU
COVID-19, H1N1 Influenza
Comparison of COVID-19 and H1N1 Influenza Pneumonia
To explore the different clinical and CT features distinguishing COVID-19 from H1N1 influenza pneumonia.
- Trial name
- NCT04933994
- Testing
- computed Tomography
- Volunteers
- 483 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Hematologic Neoplasms, Influenza
Influenza Vaccination Strategy for Patients With Hematologic Malignancy
This randomized controlled trial evaluates and compares the immunogenicity of three different influenza vaccine formulations: high-dose trivalent (HD-IIV3), MF59-adjuvanted quadrivalent (aIIV4), and standard-dose trivalent…
- Conditions
- Hematologic Neoplasms, Influenza, Immunogenicity
- Trial name
- (HEM-FLU) (NCT07485855)
- Testing
- High-dose trivalent inactivated influenza vaccine (HD-IIV3), MF59-adjuvanted quadrivalent inactivated influenza vaccine (aIIV4), Standard-dose trivalent inactivated influenza vaccine (SD-IIV3)
- Where
- South Korea
- Volunteers
- 120 people
- Sponsor
- Asan Medical Center
Influenza
Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2007/2008) When Administered to NON Elderly AND Elderly Subjects
To evaluate the antibody response to each influenza vaccine antigen when administering a single dose to subjects aged > 18 years
- Trial name
- NCT00518726
- Testing
- Surface Antigen, Inactivated, Adjuvanted, Influenza Vaccine, Formulation 2007-2008
- Where
- 3 sites in Italy
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
Immunogenicity of Adjuvanted or Non-adjuvanted H5N1 Booster Vaccine in Adults Primed to A/VN/1194/04
This study focuses on pre-pandemic priming of man against H5 influenza with the goal of mounting a robust antibody response to small quantities of vaccine either before or during an H5 pandemic.
- Trial name
- NCT00814385
- Testing
- Aflunov (Single prime, single boost), Aflunov (Double prime, single boost), Aflunov (No prime, single boost)
- Where
- 2 sites in United Kingdom
- Volunteers
- 606 people, healthy volunteers welcome
- Sponsor
- University Hospitals, Leicester
Influenza
Influenza Burden Assessment in the United Kingdom, 1996-2008
The study will assess the burden of influenza by age, risk status, vaccination status and influenza subtype, in order to create a complete profile of the burden of influenza-related morbidity and mortality in United Kingdom from…
- Trial name
- NCT01520935
- Testing
- Data collection
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Influenza Vaccine Effectiveness
A Case Control Study of the Effectiveness of Q/LAIV Versus Inactivated Influenza Vaccine and No Vaccine in Subjects 2-17 Years of Age
This is a post-marketing case-controlled study of the effectiveness of a quadrivalent live attenuated influenza vaccine (Q/LAIV/FluMist® Quadrivalent) versus Inactivated Influenza Vaccine (IIV) and No Vaccine in subjects 2-17…
- Trial name
- ICICLE (NCT01997450)
- Where
- 12 sites in United States, United Kingdom
- Volunteers
- 4,121 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Kidney Transplant
Cell-mediated Immune Response to Influenza Vaccine
Influenza virus is an important cause of morbidity in the transplant population and can lead to viral and bacterial pneumonia. Although the annual influenza vaccine is recommended for organ transplant patients, studies have shown…
- Trial name
- NCT00677547
- Where
- Canada
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Alberta
Influenza
Immune Responses to H5N1 Vaccine With and Without AS03 Adjuvant
Background: Adjuvants are substances included in vaccines that stimulate the immune system and increase the body's response to the vaccine. The AS03 adjuvant is used in seasonal flu vaccines in Europe.
- Trial name
- NCT01578317
- Testing
- H5N1 vaccine plus AS03 adjuvant, H5N1 vaccine without adjuvant
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Heterologous Effects of Vaccines
Heterologous Effect of Diptheria, Tetanus, Acellular Pertussis Vaccination on Influenza Challenge in the Elderly
Vaccines can have non-targeted or heterologous (also called non-specific) immunological effects on the immune system i.e. effects other than inducing an immune response against the disease targeted by the vaccine.
- Trial name
- NCT02765126
- Testing
- Seasonal influenza vaccine, Diphtheria-tetanus-acellular pertussis vaccine
- Where
- Australia
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Clifford Craig Medical Research Trust
Prophylaxis Against Influenza
To Evaluate the Effectiveness(Immunogenicity) and Safety of 'GC3102C' Administered Intramuscularly in Healthy Adults
The primary objective is to demonstrate the immunological non-inferiority between GC3102C and GC FLU inj. influenza vaccines by assessing geometric mean titers(GMTs) in healthy adults
- Trial name
- NCT01750814
- Testing
- GC3102C, GC FLU inj.
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Green Cross Corporation
Meningitis, Influenza
Phase 3 Study of A Group A, C Polysaccharide Meningococcal and Type b Haemophilus Influenzal Conjugate Vaccine
Haemophilus influenzae is an important pathogen which can cause primary infection and respiratory viral infection in infants and leaded to secondary infections.
- Trial name
- NCT01580033
- Testing
- A+C+hib Conjugate Vaccine, A+C Vaccine, Hib vaccine
- Where
- China
- Volunteers
- 900 people
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Influenza
T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 4, 2012
This study will investigate markers, mechanisms and define general predictors for immunological health by comparing influenza vaccine responses in monozygotic and dizygotic twins.
- Trial name
- NCT03022435
- Testing
- TIV, High-Dose TIV, LAIV
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Stanford University
Influenza
Immuno & Reacto of TF Trivalent Influenza Split Vaccine 2003/04 or of Std Formulation Influsplit SSW®/Fluarix™ 2003/04
The aim of the present study is to assess the reactogenicity and immunogenicity of a thiomersal-free influenza vaccine. For comparison, a group of subjects is administered the standard formulation of Influsplit SSW® 2003/2004.
- Trial name
- NCT00731393
- Testing
- Thiomersal free trivalent influenza split vaccine 2003/2004, GlaxoSmithKline Biologicals' Influsplit SSW®/Fluarix™ 2003/2004
- Where
- 13 sites in Germany
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Tuberculosis
Phase 2 Study of the ТВ/Flu-05Е Tuberculosis Vaccine
The aim of the study is to investigate immunogenicity and safety of the TB/Flu-05E single-dose intranasal vaccine for the prevention of Tuberculosis infection in BCG-vaccinated Volunteers aged 18-50 years
- Trial name
- NCT06873282
- Testing
- TB/Flu-05E
- Where
- 3 sites in Russia
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Research Institute of Influenza, Russia
Prepandemic Influenza Vaccine
Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects
The present study will evaluate the immunogenicity, safety and tolerability of two doses of monovalent inactivated influenza vaccine that is adjuvanted with MF59C.1 (MF59) and uses a surface antigen from a potential pandemic…
- Trial name
- NCT00841646
- Testing
- Monovalent inactivated influenza vaccine
- Where
- 2 sites in Hungary
- Volunteers
- 343 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 2010/2011 Season
Influenza (flu) viruses change continuously, therefore also the parts of viruses used in influenza vaccines can vary from year to year.
- Trial name
- NCT01146015
- Testing
- Trivalent influenza subunit vaccine Influvac
- Where
- 2 sites in Belgium, Germany
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Abbott Biologicals
Influenza, Human, Acute Respiratory Infection
Efficacy and Safety Study of Ingavirin® to Treat Influenza and Acute Respiratory Viral Infections in Children 7-12 y.o.
The purpose of this study is to determine whether Ingavirin ® dosed 60 mg daily is effective and safe in the treatment of influenza and other acute respiratory viral infections in 7-12 years old patients.
- Conditions
- Influenza, Human, Acute Respiratory Infection, Viral Infection, Common Cold
- Trial name
- NCT03191097
- Testing
- Ingavirin
- Where
- 11 sites in Russia
- Volunteers
- 310 people
- Sponsor
- Valenta Pharm JSC
Influenza, Human
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Influenza
This study will be divided into two substudies - Substudy A (SSA) and Substudy B (SSB) Substudy A This is a Phase 1 randomized substudy to evaluate the safety and immunogenicity of monovalent influenza modRNA vaccine (mIRV) and…
- Trial name
- NCT05052697
- Testing
- mIRV, bIRV AB, qIRV
- Where
- 100 sites in United States
- Volunteers
- 1,158 people, healthy volunteers welcome
- Sponsor
- Pfizer
Influenza
Proteomic Profiling for Influenza
The purpose of this study is to evaluate a new method of detecting the flu infection. This method may allow researchers to identify new proteins being made in response to an infection even before symptoms of the infection are…
- Trial name
- NCT00133588
- Testing
- Trivalent split Inf
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza A Subtype H7N7 Infection
Evaluating the Safety and Immune Response of an H7N7 Vaccine in Healthy Adults
H7N7 is one type of influenza virus that may pose a threat to humans if an outbreak occurs. This study will evaluate the safety and immune response to an H7N7 vaccine in people who have previously received a live attenuated…
- Trial name
- NCT01534468
- Testing
- Monovalent Influenza Subvirion Vaccine, H7N7
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.